PT  - JOURNAL ARTICLE
AU  - Nuño, Miriam
AU  - García, Yury
AU  - Rajasekar, Ganesh
AU  - Pinheiro, Diego
AU  - Schmidt, Alec J.
TI  - COVID-19 Hospitalizations in Five California Hospitals
AID  - 10.1101/2021.01.29.21250788
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.01.29.21250788
4099  - http://medrxiv.org/content/early/2021/02/01/2021.01.29.21250788.short
4100  - http://medrxiv.org/content/early/2021/02/01/2021.01.29.21250788.full
AB  - Importance Characterization of a diverse cohort hospitalized with COVID-19 in a health care system in California is needed to further understand the impact of SARS-CoV-2 and improve patient outcomes.Objectives To investigate the characteristics of patients hospitalized with COVID-19 and assess factors associated with poor outcomes.Design Patient-level retrospective cohort studySetting University of California five academic hospitals.Participants Patients ≥18 years old with a confirmed test result for SAR-CoV-2 virus hospitalized at five UC hospitals.Exposure Confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by positive results on polymerase chain reaction testing of a nasopharyngeal sample among patients requiring hospital admission.Main Outcomes and Measures Admission to the intensive care unit, death during hospitalization, and the composite of both outcomes.Results Outcomes were assessed for 4,730 patients who were discharged or died during a hospitalization. A total of 846 patients were treated at UC Davis, 1,564 UC Irvine, 1,283 UC Los Angeles, 471 UC San Diego, and 566 UC San Francisco. More than 20% of patients were ≥75 years of age (75-84: 12.3%, ≥85: 10.5%), male (56.5%), Hispanic/Latino (45.7%), and Asian (10.3%). The most common comorbidities were hypertension (35.2%), cardiac disease (33.3%), and diabetes (24.0%). The ICU admission rate was 25.2% (1194/4730), with 7.0% (329/4730) in-hospital mortality. Among patients admitted to the ICU, 18.8% (225/1194) died; 2.9% (104/3536) died without ICU admission. The rate of the composite outcome (ICU admission and/or death) was 27.4% (1,298/4,730). While controlling for comorbidities, patients of age 75-84 (OR 1.47, 95% CI: 1.11-1.93) and 85-59 (OR 1.39, 95% CI: 1.04-1.87) were more likely to experience a composite outcome than 18-34 year-olds. Males (OR 1.39, 95% CI: 1.21-1.59), and patients identifying as Hispanic/Latino (OR 1.35, 95% CI: 1.14-1.61), and Asian (OR 1.43, 95% CI: 1.23-1.82), were also more likely to experience a composite outcome than White. Patients with 5 or more comorbidities were exceedingly likely to experience a composite outcome (OR 2.74, 95% CI: 2.32-3.25).Conclusions Males, older patients, those with pre-existing comorbidities, and those identifying as Hispanic/Latino or Asian experienced an increased risk of ICU admission and/or death.Question What are the characteristics and outcomes of patients with SARS-CoV-2 infection hospitalized at five UC Health medical centers in California?Findings In this retrospective case series of 4,730 patients requiring hospitalization for COVID-19 in UC Health’s five medical centers, male (OR 1.41, 95% CI: 1.23-1.61), Hispanic/Latino (OR 1.35, 95% CI: 1.14-1.61), and Asian (OR 1.43, 95% CI: 1.12-1.82) were more likely to be admitted to the ICU and/or die after adjustment for age and comorbidity. ICU admission and/or death was more likely among older individuals and greater numbers of pre-existing conditions.Meaning This study describes the experience of a large, diverse cohort of patients with COVID-19 hospitalized in five hospitals in California between December 14, 2019 and January 6, 2021.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The University of California Health System determined that the COVID Research Data Set (CORDS), a de-identified and limited data set, was exempt from human subject protection under IRB protocol 1604619-1.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCORDS is de-identified but is still protected health information under HIPAA, and is therefore not publicly available.SARS-CoV-2 =Severe Acute Respiratory Syndrome Coronavirus 2COVID-19 =coronavirus disease 2019UC Health =University of California Five Academic Medical CentersUCD =University of California Davis, Medical CenterUCI =University of California Irvine, Medical CenterUCLA =University of California Los Angeles, Medical CenterUCSD =University of California San Diego, Medical CenterUCSF =University of California San Francisco, Medical CenterICU =Intensive Care UnitICU Days =Days spent in the Intensive Care UnitLOS =Days spent in the hospital before discharge or deathICD-10-CM =International Classification of Diseases, 10th Revision, Clinical ModificationAIAN =American Indian/Alaskan Native